ArticleCells2021

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.

Margot S F Roeten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.